RARE — Ultragenyx Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $1.50bn
- $2.35bn
- $673.00m
Ultragenyx's rare disease drug fails in late-stage trial
Brief: Ultragenyx Announces The Publication Of A Successful 96-Week Randomized, Placebo-Controlled Trial With Crossover Treatment Of Genglycos™ (Also Known As Dtx401) Aav Gene Therapy In Gsdia In The Journal Of Inherited Metabolic Disease
Brief: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
U.S. STOCKS ON THE MOVE-Walmart, Atour Lifestyle, Wolfspeed
Ultragenyx rises after securing FDA nod for rare metabolic disorder gene therapy
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder (updated)
Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod
Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary
Ultragenyx Q2 revenue rises 28% to record high, net loss narrows
Brief: Ultragenyx Q2 EPS USD -0.9
Brief: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Ultragenyx Q1 revenuedrop steeper than estimated; back FY view
Ultragenyx rises after FDA accepts marketing application for rare disease therapy
U.S. STOCKS ON THE MOVE-Sysco, Crowdstrike, GM
U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar
Brief: Ultragenyx Announces FDA Clearance Of Investigational New Drug (Ind) Application For Ux016